Capecitabine is recognized in the United States Pharmacopeia (USP), which provides a comprehensive monograph detailing its quality standards. According to the USP, Capecitabine must contain not less than 98.0% and not more than 102.0% of C₁₅H₂₂FN₃O₆, calculated on the anhydrous and solvent-free basis. The monograph also specifies identification tests, impurity limits, and assay methods to ensure the drug's purity and potency.
While specific monographs for Capecitabine in the British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP) were not identified in the provided sources, these pharmacopoeias typically align with international standards. Therefore, it is advisable to consult the latest editions of the BP, EP, and IP for any updates regarding Capecitabine.
Regarding dissolution testing, the USP General Chapter <1090> provides guidance on assessing drug product performance, including bioavailability and dissolution. This chapter outlines methodologies to evaluate how the drug releases its active ingredient, which is critical for ensuring therapeutic efficacy.
Stability testing for Capecitabine should adhere to the International Council for Harmonisation (ICH) guidelines, which define stability testing protocols across different climatic zones. These guidelines help determine the shelf life and storage conditions necessary to maintain the drug's quality over time.
In summary, compliance with the USP monograph and ICH stability guidelines is essential for ensuring the quality, safety, and efficacy of Capecitabine in the pharmaceutical supply chain.
